Down 22% in a month: Why is the Avita Medical (ASX:AVH) share price sliding again today?

The Avita Medical share price isn't catching bids today…

Shares in regenerative medicine group Avita Medical Inc (ASX: AVH) are in the red today, down 2.78% to $3.50. This means the Avita share price is now down 22.08% over the past month.

Today's falling share price comes amid an announcement from Avita Medical that it was forced to adjourn its annual general meeting (AGM) this morning.

The company was unable to conduct any business at the AGM because it did not achieve the required quorum.

The announcement was deemed non-price sensitive, however the contents are important for investors. Here are the details.

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.

Image source: Getty Images

Why did Avita adjourn its AGM?

The required quorum for the AGM was a simple majority (i.e. 50%) of Avita's common stock being represented at the meeting, either in person or via proxies.

In its announcement, Avita said the proxies it had received represented approximately 49% of its shares outstanding, including CHESS Depositary Interests (CDIs).

As such, the company adjourned its AGM to Thursday, 23 December at 8am AEDT.

The adjournment gives shareholders additional time to vote on the proposals set forth in Avita's definitive proxy statement filed with the United States Securities and Exchange Commission (SEC) and the ASX.

During the adjournment period, Avita will continue to solicit votes from its stakeholders.

Avita Medical investors on the company record as of 26 October are entitled to vote. The voting deadline is now 21 December, which is 2 days before the rescheduled AGM is due to take place. Valid proxies and CDI voting instruction forms that were submitted in time for today's meeting will still be used at the next meeting unless properly revoked.

If Avita fails to reach a quorum for the second time, it will adjourn the AGM again at an additional cost.

What does Avita do?

Avita Medical uses technology to create advanced treatments for patients with burns and chronic wounds.

Avita's first US product, the RECELL System, was approved by the US Food and Drug Administration (FDA) in 2018. It uses a small amount of a patient's own skin to create spray-on skin cells. This drastically reduces the need for donor skin and autografts.

Avita Medical share price summary

In the past 12 months, the Avita Medical share price has plunged 23% into the red.

Investors have lost 6% in value over the past 5 trading days.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »